Influence of lipid metabolism disorders on venous thrombosis risk
Aim: To investigate influence of lipid metabolism disorders on the risk of deep vein thrombosis.
Methods: A total of 200 subjects participated in the study, 100 of whom experienced DVT with or without PTE, and 100 healthy subjects representing the control group. We classified patients and controls in terms of serum concentrations of chylomicrons, LDL, IDL, VLDL and HDL particles, as those with or without hyperlipoproteinemia and in terms of serum Lp(a) lipoprotein levels, as those with hyperLp(a) lipoproteinemia (serum Lp(a) values> 0.3g /l) and those without hyperLp(a) lipoproteinemia (serum Lp (a) values <0.3g /l). Based on the modified and supplemented Fredrickson classification participants with verified existences of hyperlipoproteinemia were classified into subgroups based on the type of hyperlipoproteinemia. Unconditional logistic regression was used to calculate ORs with 95% CIs as a measure of the relative risks for venous thrombosis in participants with hyperlipoproteinemia compared with those without hyperlipoproteinemia. The analysis was adjusted for all potential confounders (age, sex, obesity) related to the functionality of the lipid metabolism, and at the same time may have an impact on the risk of venous thrombosis.
Results: The results of the comparison of the mean values of individual lipid status parameters between the patient group and the control group clearly indicate higher concentrations of total cholesterol (5.93mmol/l vs. 5.52mmol/l), total triglycerides (1.58mmol/l vs. 1.50mmol/l), and LDL-cholesterol (3.83mmol/l vs. 3.44mmol/l) in the patient group relative to the control group, with a statistically significant difference observed only in the case of LDL-cholesterol concentrations. We have found that type IIa hyperlipoproteinemia is associated with a nearly double increased risk for deep vein thrombosis (OR 1.99; Cl 1.01-3 , 90), while type IIb, IV, or hyperLp (a) lipoproteinemia didn't influence the risk (OR 1,22; 95% Cl 0.79-1.84; OR 0.89; 95% Cl 0.52-1.54 OR 1.85; 95% CI 0,84-4,04.
Conclusion: Hypercholesterolemia doubles the risk of deep vein thrombosis development.
2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5:692-9-
3. Dujmović F. et al. Praktikum iz patološke fiziologije. Novi Sad. Medicinski fakultet; 2012.
4. Heit, John A., et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Archives of internal medicine, 2000, 160.6: 761-768.
5. Virchow R. Phlogose und Thrombose im Gefäϐsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Staatsdruckerei, Frankfurt, 1856.
6. Đurđević S. Kopitović V. Kapamardžija A. Ginekologija.Novi Sad. Medicinski fakultet; 2011.
7. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-73.
8. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183-1188.
9. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J. 1994;308:891-894.
10. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospolipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691
11. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139:289-96.
12. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "The Study of Men Born in 1913". Arch Intern Med 1999; 159:1886-90.
13. Prandoni P., et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. Journal of Thrombosis and Haemostasis, 2006, 4.9: 1891-1896
14. Gordon, T. & Kannel, W.B. (1972) Predisposition to atherosclerosis in the head, heart and legs. The Framingham Study. The Journal of the American Medical Association, 221, 661.
15. Hume, M., Sevitt, S. & Thomas, D.P. (1970) Venous Thrombosis and Pulmonary Embolism. Harvard University Press, Cambridge, MA
16. Rumley, A., Emberson, J.R., Wannamethee, S.G., Lennon, L., Whincup, P.H. & Lowe, G.D. (2006) Effects of older age on fibrin D-dimer, C-reactive protein and other hemostatic and inflammatory variables in men aged 60-79 years. Journal of Thrombosis and Haemostasis, 4, 982–987
17. Smeeth, L., Cook, C., Thomas, S., Hall, A.J., Hubbard, R. & Vallance, P. (2006) Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet, 367, 1075–1079.
18. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med. 1988;318(18):1162–1173.
19. Leonardi MJ, McGory ML, Ko CY. The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials. Arch Surg. 2006;141(8):790–797.
20. Prandoni, P., Villalta, S., Tormene, D., Spiezia, L. & Pesavento, R. (2007) Immobilisation resulting from chronic medical diseases: a new risk factor for recurrent venous thromboembolism in anticoagulated patients. Journal of Thrombosis and Haemostasis, 5, 1786–1787.
21. Vaýo A, Mira Y, Ferrando F, Conteras M, Estelles A, Espańa F. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors BJH 2002; 118:255-9.
22. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161:1405-10.
23. Nowak-Goottl U. et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation, 1999, 100.7: 743-748.
24. SOFI, Francesco, et al. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. The American journal of medicine, 2007, 120.8: 728-733.
25. McColl MD, Sattar N, Ellison J, Tait RC, Walker ID, Packard CJ, et al. Lipoprotein(a), cholesterol and tryglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11:225-9.
26. Albert W., et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Archives of internal medicine, 2002, 162.10: 1182-1189.
27. Kawasaki T. et al. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thrombosis research, 1997, 88.1: 67-73.
28. Deguchi H. et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation, 2005, 112.6: 893-899.
29. Carvalho, AC., et al. Intravascular coagulation in hyperlipidemia. Thrombosis research, 1976, 8.6: 843-857.
Copyright (c) 2020 Igors Spasić, Milan Ubavić, Zorica Šumarac, Maša Todorović, Biljana Vučković
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.